Drawing for DATAOME TECHNOLOGY

USPTO serial 87048122

DATAOME TECHNOLOGY

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
HISER, CHARLES
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with DATAOME TECHNOLOGY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Peter T. Wakiyama

PETER T. WAKIYAMA PEPPER HAMILTON LLP18TH AND ARCH STREETS3000 TWO LOGAN SQUAREPHILADELPHIA, PA 19103

Goods and services

ClassDescriptionStatusFirst use
009Downloadable computer databases containing information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology; downloadable computer databases containing medical and health information on humans; ; downloadable computer software for accessing, organizing, indexing, ranking, integrating, linking, referencing, synthesizing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humans; downloadable mobile applications for mobile devices, for accessing, organizing, synthesizing, indexing, ranking, integrating, linking, referencing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humansACTIVE—
035Business consulting and research services for employers in the field of employee benefits in the nature of offering medical and health care plans to employees and their family members and domestic partners for medical and health care diagnostic and treatment support programsACTIVE—
036Financial administration of programs and services for payment and reimbursement of employee benefits in the nature of medical and health care diagnostic and treatment support programs, for employees and their family members and domestic partnersACTIVE—
038Providing access to searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information and records, molecular test results and patient specific data about or relating to humans for scientific research purposes; providing access to searchable online databases containing medical, pharmaceutical, biological, clinical, molecular, sequencing and genomic information, disease information, biomarker information and medical or health information or records about or relating to humans and patient specific data, molecular test results, and scientific research for medical diagnostic and treatment purposesACTIVE—
042Scientific consulting and research services in the fields of health care, medicine, life sciences, biotechnology, pharmaceuticals, bioinformatics, genomics and pharmaceuticals and pharmaceutical safety for scientific research purposes; Scientific consulting and research services in the nature of retrieval, integration, correlation, analysis and interpretation of genomic, sequencing, and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, medical health information patient specific data, molecular test results, data from clinical studies, and scientific research for purposes of scientific, medical and pharmaceutical research; designing and developing searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information and records, molecular test results and patient specific data about or relating to humans for scientific research purposes; providing a web site featuring non-downloadable software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for use by physicians, clinicians and other health care professionals, laboratory personnel, consultants, scientists and other researchers for conducting scientific, medical and pharmaceutical research; providing a web site featuring software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for purposes of scientific, medical and pharmaceutical research; providing online, non-downloadable mobile and web applications for mobile devices, namely, smart phones and tablets, for accessing information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology for scientific research purposes; data collection services for scientific research purposes in the fields of genomics, health care, pharmaceuticals, life sciences, bioinformatics, biotechnology and medicine; research services in the fields of retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing a web site featuring online non-downloadable computer software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing a web site featuring online non-downloadable software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing a web site featuring online non-downloadable mobile applications for mobile devices, namely, smart phones and tablets, and non-downloadable web applications accessible through the Internet all for retrieval of information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals and pharmaceutical safety, life sciences and biotechnologyACTIVE—
044Medical consulting in the fields of retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies; medical consulting services in the fields of health, medical care, biotechnology, bioinformatics, life sciences, pharmaceuticals and medicine; providing medical information in the fields of health, healthcare, life sciences, biotechnology, pharmaceuticals and pharmaceutical safety, bioinformatics, and genetic testing for medical purposes; medical consulting services with respect to the treatment and diagnosis of individuals; providing medical information on drug safety and drug compatibility in relation to therapy and the treatment of individuals; medical consulting services in the fields of diagnostics and patient treatment and treatment protocolsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Aug 17, 2020MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 17, 2020ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 15, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 14, 2020EX5GSOU EXTENSION 5 GRANTED—
Jan 9, 2020EXT5SOU EXTENSION 5 FILED—
Jan 9, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 13, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 11, 2019EX4GSOU EXTENSION 4 GRANTED—
Jul 11, 2019EXT4SOU EXTENSION 4 FILED—
Jul 11, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 15, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 11, 2019TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 11, 2019EX3GSOU EXTENSION 3 GRANTED—
Jan 11, 2019EXT3SOU EXTENSION 3 FILED—
Jan 11, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 13, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 11, 2018EX2GSOU EXTENSION 2 GRANTED—
Jul 11, 2018EXT2SOU EXTENSION 2 FILED—
Jul 11, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 11, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 21, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 20, 2018EX1GSOU EXTENSION 1 GRANTED—
Feb 20, 2018AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Feb 5, 2018NREVNOTICE OF REVIVAL - E-MAILED—
Feb 5, 2018TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Feb 5, 2018PETGPETITION TO REVIVE-GRANTED—
Feb 5, 2018PROATEAS PETITION TO REVIVE RECEIVED—
Jan 11, 2018EXT1SOU EXTENSION 1 FILED—
Jul 11, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 16, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 16, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 26, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 6, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 5, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 5, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 5, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 27, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 16, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 15, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 15, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 16, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 16, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 16, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 8, 2016DOCKASSIGNED TO EXAMINER—
Jun 2, 2016MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jun 1, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 27, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance